CellaVision AB (CHIX:CEVIS) Issuance of Debt: kr0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CEVIS CellaVision AB CHIX:CEVIS
94 GF Score
Price kr160.20
GF Value kr243.89
! 1 Warning Sign
View Full Analysis

What is CellaVision AB Issuance of Debt?

CellaVision AB CHIX:CEVIS 94 Issuance of Debt is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:CEVIS with a GF Score™ of 94/100 and a GF Value™ of kr243.89. The stock has 1 warning sign investors should review.

CellaVision AB's Issuance of Debt for the three months ended in Mar. 2026 was kr0.0 Mil.

CellaVision AB's Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.0 Mil.

CellaVision AB Issuance of Debt Related Terms

CellaVision AB Issuance of Debt Historical Data

* Premium members only.

The historical data trend for CellaVision AB's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB Issuance of Debt Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.71 0.00 0.00 0.00 0.00

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:CEVIS
94GF Score
CellaVision AB CHIX:CEVIS
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of kr0.0 Mil mean?
CellaVision AB (CHIX:CEVIS) has a Issuance of Debt of kr0.0 Mil as of Mar. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on CellaVision AB and its competitors.
Is CellaVision AB's Issuance of Debt too high?
CellaVision AB's current Issuance of Debt is kr0.0 Mil. Overall, CellaVision AB has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Issuance of Debt compare to ABT and SYK?
CellaVision AB's Issuance of Debt of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Medical Devices & Instruments company?
A good Issuance of Debt depends on the Medical Devices & Instruments industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on CellaVision AB and its competitors. CellaVision AB's current Issuance of Debt is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Issuance of Debt of kr0.0 Mil. The stock's GF Value™ is kr243.89, compared to a current price of kr160.20 — trading 34.3% below its estimated fair value. The current Issuance of Debt is kr0.0 Mil. CellaVision AB's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Issuance of Debt is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of kr160.20 is trading 34.3% below its estimated GF Value™ of kr243.89.

Key valuation signals for CHIX:CEVIS:

  • Issuance of Debt: kr0.0 Mil
  • GF Value™: kr243.89 vs. price of kr160.20 (34.3% below fair value)
  • GF Score™: 94/100 with 1 warning sign

No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
94GF Score

Get the complete analysis for CHIX:CEVIS

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr160.20
Price
kr243.89
GF Value